Immunome – a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies – announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals (a clinical-stage oncology company) to acquire AL102 and related drug candidate AL101 from Ayala.
Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing. And it will pay up to an additional $37.5 million in development and commercial milestone payments. The completion of the transaction is subject to customary conditions, including Ayala obtaining the requisite stockholder approval.
AL102 is an investigational small molecule gamma secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. AL102 is a potential once-daily oral treatment for desmoid tumors. Data from clinical trials have shown AL102 may be more effective in treating desmoid tumors than OGSIVEO (nirogacestat), which recently became the first treatment approved for desmoid tumors by the U.S. Food and Drug Administration (FDA) in November 2023.
The Phase 2 portion of the RINGSIDE study demonstrated clinically meaningful anti-tumor activity across multiple parameters. And the data showed high objective response rates, including 75% of evaluable patients (and 64% of intent-to-treat patients) in the 1.2 mg once daily arm, the dose being evaluated in the current Phase 3 trial. Plus, patients receiving the 1.2 mg daily dose experienced a median best reduction in tumor volume of 88% as measured by serial MRI exams, as of the previously reported July 5, 2023 data cut-off, and also demonstrated improvement in other radiographic parameters.
It is estimated that as many as 1,650 people in the U.S. are diagnosed annually with desmoid tumors (also known as aggressive fibromatosis), and the population prevalence is much higher. And desmoid tumors, which occur predominantly in young adults, can cause significant pain and disability. Available non-pharmacologic therapies like surgery or radiation are often ineffective and can lead to long term complications, and unapproved targeted therapies lack long-term potency. In November 2023, AL102 was granted Orphan Drug Designation by the FDA.
A.G.P./Alliance Global Partners is acting as strategic advisor to Ayala Pharmaceuticals, Inc.in connection with the transaction.
KEY QUOTES:
“Immunome is committed to advancing therapies with best-in-class potential. We are especially optimistic about the rapidity and depth of the tumor responses observed in the Phase 2 portion of RINGSIDE. AL102 will complement our existing portfolio of targeted cancer agents that are approaching Phase 1 trials. As we complete the work required to advance AL102 to NDA submission, our goal is to bring clinical benefit to an underserved patient population while generating substantial value for stockholders. We also plan to investigate other populations of cancer patients that could benefit from treatment with AL102.”
- Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome
“We are pleased that this exciting molecule will be advanced by Immunome and its team of highly-experienced drug developers which, we believe, maximizes the ability to conclude the RINGSIDE study and bring our lead asset to commercialization. I am proud of the work Ayala has done over the last several years to assemble compelling clinical data and reach this point.”
- Ken Berlin, CEO of Ayala Pharmaceuticals
